Analyst Price Targets — BMEA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 24, 2025 1:27 pm | — | Oppenheimer | $10.00 | $2.79 | TheFly | Biomea Fusion price target lowered to $10 from $50 at Oppenheimer |
| October 31, 2024 7:29 am | Joseph Catanzaro | Piper Sandler | $19.00 | $10.34 | TheFly | Biomea Fusion price target raised to $19 from $10 at Piper Sandler |
| October 30, 2024 4:44 am | Peter Lawson | Barclays | $11.00 | $12.06 | TheFly | Biomea Fusion price target raised to $11 from $9 at Barclays |
| October 22, 2024 6:58 am | Joseph Pantginis | H.C. Wainwright | $40.00 | $11.24 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Biomea Fusion Inc. (BMEA) |
| September 27, 2024 8:41 am | Joseph Catanzaro | Piper Sandler | $10.00 | $9.90 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Biomea Fusion Inc. (BMEA) |
| June 7, 2024 8:34 am | Joseph Pantginis | H.C. Wainwright | $15.00 | $4.24 | TheFly | Biomea Fusion price target lowered to $15 from $50 at H.C. Wainwright |
| June 7, 2024 7:25 am | George Farmer | Scotiabank | $21.00 | $11.27 | StreetInsider | Biomea Fusion Inc. (BMEA) PT Lowered to $21 at Scotiabank |
| June 7, 2024 4:48 am | Peter Lawson | Barclays | $5.00 | $11.27 | TheFly | Biomea Fusion downgraded to Equal Weight from Overweight at Barclays |
| June 14, 2022 11:04 am | Joseph Pantginis | H.C. Wainwright | $16.00 | $8.50 | Pulse 2.0 | Biomea Fusion (BMEA) Stock Price: $16 Target And Buy Rating |
Latest News for BMEA
Biomea Fusion, Inc. (NASDAQ: BMEA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025, and provided a business update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BMEA.
U.S. House Trading
No House trades found for BMEA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.